You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Details for New Drug Application (NDA): 217186


✉ Email this page to a colleague

« Back to Dashboard


NDA 217186 describes CREXONT, which is a drug marketed by Impax and is included in one NDA. It is available from one supplier. There are twenty-nine patents protecting this drug. Additional details are available on the CREXONT profile page.

The generic ingredient in CREXONT is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
Summary for 217186
Tradename:CREXONT
Applicant:Impax
Ingredient:carbidopa; levodopa
Patents:29
Pharmacology for NDA: 217186
Suppliers and Packaging for NDA: 217186
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CREXONT carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 217186 NDA Amneal Pharmaceuticals LLC 64896-967 64896-967-16 1 BOTTLE in 1 CARTON (64896-967-16) / 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
CREXONT carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 217186 NDA Amneal Pharmaceuticals LLC 64896-967 64896-967-23 1 BOTTLE in 1 CARTON (64896-967-23) / 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength35MG;140MG
Approval Date:Aug 7, 2024TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 7, 2027
Regulatory Exclusivity Use:NEW PRODUCT
Patent:⤷  Get Started FreePatent Expiration:Oct 7, 2034Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PARKINSON'S DISEASE
Patent:⤷  Get Started FreePatent Expiration:Oct 7, 2034Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PARKINSON'S DISEASE

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links